Caroline Ford

List of Publications by Year in Descending Order

48 papers	1,395 citations	22 h-index	37 g-index
59 ext. papers	1,676 ext. citations	5.7 avg, IF	4.62 L-index

#	Paper	IF	Citations
48	The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma. *ELife*, **2021**, 10,	8.9	2
47	Comparison of total and endometrial circulating cell-free DNA in women with and without endometriosis.. *Reproductive BioMedicine Online*, **2021**,	4	1
46	ROR1 and ROR2 expression in pancreatic cancer. *BMC Cancer*, **2021**, 21, 1199	4.8	0
45	An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles. *Journal of Materials Chemistry B*, **2021**, 9, 9123-9135	7.3	3
44	Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation. *PLoS ONE*, **2021**, 16, e0250561	3.7	1
43	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. *British Journal of Cancer*, **2021**, 125, 265-276	8.7	1
42	ROR2 Is Epigenetically Regulated in Endometrial Cancer. *Cancers*, **2021**, 13,	6.6	4
41	Sex Bias in Cohorts Included in Sports Medicine Research. *Sports Medicine*, **2021**, 51, 1799-1804	10.6	8
40	Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. *Gynecologic Oncology*, **2021**, 162, 720-727	4.9	1
39	The untapped potential of ascites in ovarian cancer research and treatment. *British Journal of Cancer*, **2020**, 123, 9-16	8.7	27
38	Target sequence heterogeneity causes the Vhook effectVin fluorescent dye-based quantitative PCR. *BioTechniques*, **2020**, 69, 80-83	2.5	2
37	ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target. *Scientific Reports*, **2020**, 10, 13906	4.9	7
36	A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles. *Biomaterials Science*, **2019**, 7, 1652-1660	7.4	17
35	Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight. *PLoS ONE*, **2019**, 14, e0224338	3.7	6
34	Selective modulation of Wnt-binding receptor tyrosine kinase ROR2 expression by human cytomegalovirus regulates trophoblast migration. *Journal of General Virology*, **2019**, 100, 99-104	4.9	0
33	ROR1 and ROR2 play distinct and opposing roles in endometrial cancer. *Gynecologic Oncology*, **2018** , 148, 576-584	4.9	17
32	I-AbACUS: a Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell Assays. *Scientific Reports*, **2018**, 8, 3814	4.9	4

31	An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target. *Endocrine-Related Cancer*, **2018**,	5.7	24
30	Comment on: Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia. *Journal of Maternal-Fetal and Neonatal Medicine*, **2017**, 30, 1085-1086	2	2
29	Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma. *Molecular Diagnosis and Therapy*, **2017**, 21, 563-570	4.5	44
28	Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer. *Translational Oncology*, **2017**, 10, 346-356	4.9	12
27	Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. *Oncotarget*, **2017**, 8, 112727-112738	3.3	22
26	Validation of specificity of antibodies for immunohistochemistry: the case of ROR2. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 99-108	5.1	8
25	Wnt signalling in gynaecological cancers: A future target for personalised medicine?. *Gynecologic Oncology*, **2016**, 140, 345-51	4.9	27
24	ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration. *BMC Cancer*, **2016**, 16, 508	4.8	23
23	Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. *Oncogenesis*, **2016**, 5, e226	6.6	36
22	Human Cytomegalovirus Modulates Expression of Noncanonical Wnt Receptor ROR2 To Alter Trophoblast Migration. *Journal of Virology*, **2016**, 90, 1108-15	6.6	19
21	The Wnt pathway: a key network in cell signalling dysregulated by viruses. *Reviews in Medical Virology*, **2016**, 26, 340-55	11.7	27
20	Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. *Molecular Cancer Research*, **2016**, 14, 1217-1228	6.6	10
19	Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. *Oncotarget*, **2015**, 6, 40310-26	3.3	46
18	Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. *Journal of Cancer Research and Clinical Oncology*, **2015**, 141, 243-54	4.9	48
17	The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. *Gynecologic Oncology*, **2014**, 134, 338-45	4.9	46
16	The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. *BMC Cancer*, **2013**, 13, 174	4.8	84
15	The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. *International Journal of Cancer*, **2013**, 133, 779-87	7.5	53
14	The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells. *PLoS ONE*, **2013**, 8, e54362	3.7	68

13	Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. *PLoS ONE*, **2012**, 7, e31885	3.7	47
12	Mouse mammary tumor like virus sequences in breast milk from healthy lactating women. *Breast Cancer Research and Treatment*, **2011**, 129, 149-55	4.4	24
11	Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3919-24	11.5	20
10	The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer. *Cell Cycle*, **2009**, 8, 1838-42	4.7	13
9	Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. *British Journal of Cancer*, **2007**, 96, 808-14	8.7	102
8	Sensing extracellular matrix: an update on discoidin domain receptor function. *Cellular Signalling*, **2006**, 18, 1108-16	4.9	264
7	Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer. *Journal of Clinical Pathology*, **2006**, 59, 1287-92	3.9	25
6	Mouse mammary tumor-like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer. *Clinical Cancer Research*, **2004**, 10, 4417-9	12.9	31
5	Mouse mammary tumor virus-like RNA transcripts and DNA are found in affected cells of human breast cancer. *Clinical Cancer Research*, **2004**, 10, 7284-9	12.9	38
4	Progression from normal breast pathology to breast cancer is associated with increasing prevalence of mouse mammary tumor virus-like sequences in men and women. *Cancer Research*, **2004**, 64, 4755-9	10.1	46
3	Elevated expression of the tumor suppressing protein p53 is associated with the presence of mouse mammary tumor-like env gene sequences (MMTV-like) in human breast cancer. *Breast Cancer Research and Treatment*, **2004**, 87, 13-7	4.4	11
2	Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women. *Clinical Cancer Research*, **2003**, 9, 1118-20	12.9	67
1	The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ER negative breast cancer		2